Do you recommend stopping olaratumab in patients receiving doxorubicin/olaratumab for treatment of advanced sarcoma?
Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combination, would you discontinue olaratumab?
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · Rutgers RWJ Medical School
Answered on
Yes, we have stopped since this data came out. Am continuing either with single agent doxorubicin or addition of a second agent such as ifosfamide in select patients.
Join for free or sign in to see the full answer